Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

Cited In for PubMed (Select 15772088)

1.

The promise and perils of HDAC inhibitors in neurodegeneration.

Didonna A, Opal P.

Ann Clin Transl Neurol. 2015 Jan;2(1):79-101. doi: 10.1002/acn3.147. Epub 2014 Dec 3. Review.

2.

Spinal Muscular Atrophy Therapeutics: Where do we Stand?

d'Ydewalle C, Sumner CJ.

Neurotherapeutics. 2015 Apr;12(2):303-16. doi: 10.1007/s13311-015-0337-y.

3.

Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion.

Tremolizzo L, Sala G, Conti E, Rodriguez-Menendez V, Fogli A, Michelucci A, Simi P, Penco S, Lunetta C, Corbo M, Ferrarese C.

Case Rep Neurol Med. 2014;2014:216094. doi: 10.1155/2014/216094. Epub 2014 Jul 17.

4.

The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy.

Liu H, Yazdani A, Murray LM, Beauvais A, Kothary R.

PLoS One. 2014 Jul 1;9(7):e101225. doi: 10.1371/journal.pone.0101225. eCollection 2014.

5.

Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts.

Sitarz KS, Elliott HR, Karaman BS, Relton C, Chinnery PF, Horvath R.

Mol Genet Metab. 2014 May;112(1):57-63. doi: 10.1016/j.ymgme.2014.03.006. Epub 2014 Mar 28.

6.

Histone deacetylases and their role in motor neuron degeneration.

Lazo-Gómez R, Ramírez-Jarquín UN, Tovar-Y-Romo LB, Tapia R.

Front Cell Neurosci. 2013 Dec 5;7:243. doi: 10.3389/fncel.2013.00243. Review.

7.

Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy.

Mohseni J, Zabidi-Hussin ZA, Sasongko TH.

Genet Mol Biol. 2013 Sep;36(3):299-307. doi: 10.1590/S1415-47572013000300001. Epub 2013 Aug 30. Review.

8.

Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Lunke S, El-Osta A.

Neurotherapeutics. 2013 Oct;10(4):677-87. doi: 10.1007/s13311-013-0209-2. Review.

9.

Spinal muscular atrophy: an update on therapeutic progress.

Seo J, Howell MD, Singh NN, Singh RN.

Biochim Biophys Acta. 2013 Dec;1832(12):2180-90. doi: 10.1016/j.bbadis.2013.08.005. Epub 2013 Aug 27. Review.

10.

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ.

EMBO Mol Med. 2013 Jul;5(7):1035-50. doi: 10.1002/emmm.201202305. Epub 2013 Jun 5.

11.

SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy.

Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Schroth MK, D'Anjou G, LaSalle B, Prior TW, Sorenson S, Maczulski JA, Swoboda KJ; Project Cure Spinal Muscular Atrophy Investigators Network.

Muscle Nerve. 2014 Feb;49(2):187-92.

12.

Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy.

Sandi C, Al-Mahdawi S, Pook MA.

Genet Res Int. 2013;2013:852080. doi: 10.1155/2013/852080. Epub 2013 Feb 19.

13.

A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.

Zhou H, Janghra N, Mitrpant C, Dickinson RL, Anthony K, Price L, Eperon IC, Wilton SD, Morgan J, Muntoni F.

Hum Gene Ther. 2013 Mar;24(3):331-42. doi: 10.1089/hum.2012.211. Epub 2013 Mar 6.

14.

SMN-inducing compounds for the treatment of spinal muscular atrophy.

Lorson MA, Lorson CL.

Future Med Chem. 2012 Oct;4(16):2067-84. doi: 10.4155/fmc.12.131. Review.

15.

Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.

Schreml J, Riessland M, Paterno M, Garbes L, Roßbach K, Ackermann B, Krämer J, Somers E, Parson SH, Heller R, Berkessel A, Sterner-Kock A, Wirth B.

Eur J Hum Genet. 2013 Jun;21(6):643-52. doi: 10.1038/ejhg.2012.222. Epub 2012 Oct 17.

16.

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

Soragni E, Xu C, Plasterer HL, Jacques V, Rusche JR, Gottesfeld JM.

J Child Neurol. 2012 Sep;27(9):1164-73. doi: 10.1177/0883073812448533. Epub 2012 Jul 4. Review.

17.

Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration.

Rossi L, Valle C, Carrì MT.

Int J Cell Biol. 2012;2012:908724. doi: 10.1155/2012/908724. Epub 2012 May 17.

18.
19.

SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.

Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, LaSalle B, Prior TW, Sorenson S, Maczulski JA, Bromberg MB, Chan GM, Swoboda KJ; Project Cure Spinal Muscular Atrophy Investigators' Network.

PLoS One. 2011;6(7):e21296. doi: 10.1371/journal.pone.0021296. Epub 2011 Jul 6.

20.

Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice.

Kwon DY, Motley WW, Fischbeck KH, Burnett BG.

Hum Mol Genet. 2011 Sep 15;20(18):3667-77. doi: 10.1093/hmg/ddr288. Epub 2011 Jun 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk